Expression of PD-1 and Its Ligands, PD-L1 and PD-L2, in Smokers and Never Smokers with KRAS-Mutant Lung Cancer.
about
Current Status and Perspective of Immunotherapy in Gastrointestinal CancersEvaluation of PD-L1 Expression in Tumor Tissue of Patients with Lung Carcinoma and Correlation with Clinical and Demographic Data.Programmed cell death ligand-1 (PD-L1) expression by immunohistochemistry: could it be predictive and/or prognostic in non-small cell lung cancer?Multiparametric profiling of non-small-cell lung cancers reveals distinct immunophenotypes.Clinical significance of PD-L1 and PD-L2 copy number gains in non-small-cell lung cancer.Induction of Patient-Derived Xenograft Formation and Clinical Significance of Programmed Cell Death Ligand 1 (PD-L1) in Lung Cancer Patients.PD-L1 Expression in Lung Cancer.A catalogue of treatment and technologies for malignant pleural mesothelioma.Targeting the KRAS Pathway in Non-Small Cell Lung Cancer.Inflammation as a driver and vulnerability of KRAS mediated oncogenesisImmune checkpoint blockade as a potential therapeutic target in non-small cell lung cancer.Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response.KRAS mutation-induced upregulation of PD-L1 mediates immune escape in human lung adenocarcinoma.PD-L1 protein expression assessed by immunohistochemistry is neither prognostic nor predictive of benefit from adjuvant chemotherapy in resected non-small cell lung cancer.High expression of programmed cell death 1 ligand 1 in lung adenocarcinoma is a poor prognostic factor particularly in smokers and wild-type epidermal growth-factor receptor cases.Aligning Digital CD8(+) Scoring and Targeted Next-Generation Sequencing with PD-L1 Expression: A Pragmatic Approach in Early-Stage Squamous Cell Lung Carcinoma.Relationship of tumor PD-L1 expression with EGFR wild-type status and poor prognosis in lung adenocarcinoma.A systematic and genome-wide correlation meta-analysis of PD-L1 expression and targetable NSCLC driver genes.PD-1 expression in head and neck squamous cell carcinomas derives primarily from functionally anergic CD4+ TILs in the presence of PD-L1+ TAMs.Treating KRAS-mutant NSCLC: latest evidence and clinical consequences.Biology of invasive mucinous adenocarcinoma of the lung.Heterogeneous expression of PD-L1 in pulmonary squamous cell carcinoma and adenocarcinoma: implications for assessment by small biopsy.Prognostic value of PD-L1 expression in combination with CD8+ TILs density in patients with surgically resected non-small cell lung cancer.Implications of KRAS mutations in acquired resistance to treatment in NSCLC.[Advances of the Role of Lung Cancer Driver Gene and PD-1/PD-L1 Pathway Interaction in the Tumorigenesis and Progression of Non-small Cell Lung Cancer].Two immune-enhanced molecular subtypes differ in inflammation, checkpoint signaling and outcome of advanced head and neck squamous cell carcinoma.PD-L1 expression testing in non-small cell lung cancer.Immune Dysregulation in Cancer Patients Undergoing Immune Checkpoint Inhibitor Treatment and Potential Predictive Strategies for Future Clinical Practice.Impact of heavy smoking on the benefits from first-line EGFR-TKI therapy in patients with advanced lung adenocarcinoma.Implementation of immunotherapy in the treatment of advanced non-small cell lung cancer (NSCLC).Role of Immunotherapy for Oncogene-Driven Non-Small Cell Lung CancerNew strategies in immunotherapy for lung cancer: beyond PD-1/PD-L1Expression of the Vesicular Monoamine Transporter Gene Solute Carrier Family 18 Member 1 () in Lung CancerPersonalized therapy for lung cancer: Striking a moving target
P2860
Q28076970-666FE23C-7829-4D1A-B150-C296C3BA58B4Q31137039-0452BA43-2C6A-42EE-A5A8-9BB84A1C94F1Q37094056-B075F98D-1A69-42C7-AD76-3078FFED4E4CQ37277198-51CA9431-62BA-4070-8AB0-0BE3FA210A4DQ37362623-81CD3F1C-DCF1-44E6-8646-C408AD6D935FQ37381288-71713E3D-81B0-4ABE-9FA0-78CEB6393B1AQ37704352-427789BD-A560-4F0F-954E-BECAB62BF246Q38760623-140DC8BB-1AF3-412A-9AFF-C5798F26816EQ38799845-4D62BAE3-2A54-4F18-A59A-9AEE397FCDA2Q38864070-CF1A5A6D-F912-43F7-8882-B8E048C44C18Q38899873-193EE432-E1B0-4A12-82D9-67381825413EQ39194722-07834F39-3063-41DC-9982-1A2C6354200AQ40223999-65E81FA0-1FBD-43FF-84CD-1B5D0B936108Q40358673-874F31D1-3E17-4BAD-9170-009085352927Q40424521-50BEDBBC-B513-45C5-BA73-1D848A7C0F6EQ40496586-1B82E13A-58C3-4830-85FE-A01DCB5F16E2Q40626934-408454F5-C756-40A4-ADE9-B8A0C792D393Q41306256-21E60613-46E0-4BE3-893E-16B91FE046FAQ41994346-767114F3-21C4-4DF3-97B2-AE340485D16CQ42820759-ED9C8089-7942-4EF5-861A-50DE31925ADDQ43874020-BD2DFD78-725C-4DFB-8215-9A1C1FC45C93Q48088758-FA420783-8732-4477-B272-36B59AC1266BQ48248023-BF97914C-A570-43FD-988A-334F0A700C63Q49787333-E37CEC38-EB2C-4A68-9A4D-C18742D39AE9Q49790309-4197A1E6-160B-41DA-81E5-0F61EFA8CF9AQ50545401-DE2A69A2-9A76-4041-82EE-A09062EF0FF1Q52584388-FB35F487-4BAD-4B30-9564-53F2E1253CE9Q53695267-9472601D-174C-469A-8ADD-672745FDC43CQ54123954-F7DA777E-028B-4E52-AF34-16791F24DE98Q55008531-4E225206-EB9B-4B33-A504-D8257D20171AQ57174372-E0137D44-A2D1-4201-B400-82890005B1B7Q58740200-CD7800BC-54D2-4B26-9FEC-94C4C4C53078Q58766038-3137D4F2-28D5-4FF9-BA3C-C1AC041A3C6AQ58792324-5BC89BD5-6871-43D7-9A50-BC5376D54179
P2860
Expression of PD-1 and Its Ligands, PD-L1 and PD-L2, in Smokers and Never Smokers with KRAS-Mutant Lung Cancer.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh-hant
name
Expression of PD-1 and Its Lig ...... with KRAS-Mutant Lung Cancer.
@en
Expression of PD-1 and Its Lig ...... with KRAS-Mutant Lung Cancer.
@nl
type
label
Expression of PD-1 and Its Lig ...... with KRAS-Mutant Lung Cancer.
@en
Expression of PD-1 and Its Lig ...... with KRAS-Mutant Lung Cancer.
@nl
prefLabel
Expression of PD-1 and Its Lig ...... with KRAS-Mutant Lung Cancer.
@en
Expression of PD-1 and Its Lig ...... with KRAS-Mutant Lung Cancer.
@nl
P2093
P50
P1476
Expression of PD-1 and Its Lig ...... with KRAS-Mutant Lung Cancer.
@en
P2093
Christine Lydon
David M Jackman
F Stephen Hodi
Geoffrey R Oxnard
Gordon J Freeman
Lynette M Sholl
Pasi A Jänne
Scott J Rodig
Xiaoyun Liao
P304
P356
10.1097/JTO.0000000000000687
P577
2015-12-01T00:00:00Z